MNPR · Monopar Therapeutics · Documents

$71.42 +4.20 (+6.25%) At close · Nov 6

Russell 2000 member Rebalance outlook locked

Market Cap

$479.38M

6.71M

Volume · Nov 6 94.21K Avg daily vol (3M) 164.19K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

2024

Aug 21

Current report 8-K

Regulation FD disclosure

Aug 14

Current report 8-K

Regulation FD disclosure

Aug 9

Current report 8-K

Financial results, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Aug 9

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Net loss $1.72M

Jul 22

Proxy statement DEF 14A Meeting Aug 5, 2024

Proxy statement

Jul 22

Annual report to holders ARS

Annual report to holders

Jul 11

Proxy statement PRE 14A Meeting Aug 5, 2024

Proxy statement

Jul 9

Current report 8-K

Regulation FD disclosure

Jun 11

Current report 8-K

Regulation FD disclosure

Jun 10

Current report 8-K

Regulation FD disclosure

May 24

Current report 8-K Events of May 23

Director or officer change, or executive pay, Regulation FD disclosure

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Net loss $1.64M

Apr 16

Current report 8-K

Regulation FD disclosure

Apr 10

Current report 8-K

Regulation FD disclosure

Mar 28

Current report 8-K

Financial results

Mar 28

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Net loss $8.4M

Mar 7

Current report 8-K

Regulation FD disclosure

Mar 5

Current report 8-K

Regulation FD disclosure

Feb 28

Current report 8-K Events of Feb 27

Delisting notice or listing transfer

Feb 27

Current report 8-K

Regulation FD disclosure

Feb 22

Current report 8-K

Regulation FD disclosure

Feb 20

Current report 8-K

Regulation FD disclosure

2023

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Net loss $1.95M

Nov 1

Current report 8-K

Regulation FD disclosure

Aug 30

Current report 8-K Events of Aug 28

Delisting notice or listing transfer

Aug 10

Current report 8-K

Financial results

Aug 10

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net loss $2.2M

Aug 8

Current report 8-K

Regulation FD disclosure

Jul 11

Current report 8-K

Regulation FD disclosure

Jun 28

Current report 8-K Events of Jun 27

Shareholder vote results

Jun 1

Current report 8-K

Regulation FD disclosure

May 11

Current report 8-K

Financial results

May 11

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $2.43M

Apr 28

Proxy statement DEF 14A Meeting Jun 27, 2023

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders

Apr 28

Proxy statement DEFA14A

Proxy statement

Mar 27

Current report 8-K

Regulation FD disclosure, Other events

Mar 23

Current report 8-K

Financial results

Mar 23

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $10.52M

Feb 27

Current report 8-K

Regulation FD disclosure

Feb 14

Current report 8-K

Regulation FD disclosure

Jan 26

Current report 8-K

Regulation FD disclosure

Jan 18

Current report 8-K

Regulation FD disclosure

2022

Dec 21

Registration statement S-3

Registration statement

Dec 12

Current report 8-K

Regulation FD disclosure

Nov 16

Current report 8-K

Regulation FD disclosure

Nov 10

Current report 8-K

Financial results

Nov 10

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $2.4M

Showing 51–100 of 166 documents

Key facts CIK 1645469 CUSIP 61023L207 13F (30d) 28 filings 24 filers Visit website Investor relations